Value of Color Doppler Echocardiography for Predicting Heart Failure After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Authors: Lingyun Ren, Zehao Hu, Zihui Huang, Liaohang Xu Published: 2026 ABSTRACT AbstractPurposeTo evaluate the role of color Doppler echocardiography in assessing ventricular remodeling and post-percutaneous coronary intervention (PCI) heart failure (HF) in patients with acute myocardial infarction (AMI).Methods81 AMI patients admitted to our hospital were selected for retrospective analysis, including 49 patients who underwent PCI (research group, RG) and 32 patients who did not undergo PCI (control group, CG). Both groups of patients were followed up for 6 months. Left ventricular (LV) end-diastolic volume (LVEDV), LV end-diastolic dimension (LVEDD), LV end-diastolic dimension (LVESD) and LV ejection fraction (LVEF) were measured using a Philips iE33 ultrasound system. To assess ventricular remodeling dynamically, LVEDVI was additionally measured at 7 days (T2), 1 month (T3), and 6 months (T4) after treatment, and ΔLVEDVI was calculated as the difference between LVEDVI at each follow‑up time point and the baseline value at T1. Receiver operating characteristic (ROC) curve was used to analyze the sensitivity of LVEDD, LVESD and LVEF to predict HF. Multivariate logistic regression analysis was used to analyze the factors associated with HF progression.ResultsElevated ΔLVEDVI levels was observed in both cohorts at T2-T4 compared with the value at T1, with significantly lower ΔLVEDVI in the RG than in the CG at each time point (P<0.05). Among the 11 patients who developed post-PCI HF in the research group, significant increases in LVEDD and LVESD and a significant decrease in LVEF (P<0.05). Based on ROC analysis, color Doppler echocardiography demonstrated excellent diagnostic performance for post-PCI HF (P<0.05). The number of coronary artery lesions, Gensini score, hypertension, and color Doppler echocardiography results at T1 were independent risk factors for post-PCI HF (P<0.05).ConclusionColor Doppler echocardiography demonstrated excellent performance in evaluating ventricular remodeling and post-PCI HF in AMI patients and may provide a reliable reference for future clinical management of AMI.Keywords: color doppler echocardiography, acute myocardial infarction, heart failure, ventricular remodeling Introduction Acute myocardial infarction (AMI), defined as the myocardial necrosis caused by acute and persistent ischemia and hypoxia of coronary arteries, presents a rising incidence in people under 45 years old and has become the leading cardiovascular disease threatening human life and health.1 According to statistics, the current incidence of AMI is about 500–90/100,000 worldwide, and it is even higher in some developed countries.2 Clinically, AMI may be caused by any factor that predisposes to thrombosis, intravascular plaque detachment, coronary artery spasm, or stenosis.3 However, strenuous exercise, excessive fatigue, high-fat diet, mood swings and weather changes, which are common in life, are all potential threats to AMI.4 Over time, the size, morphology, tissue structure and function of the patient’s left ventricle will be changed to a certain extent, which is called post-infarction ventricular remodeling—an important pathophysiological process in patients with heart failure (HF) and one of the important factors affecting patient long-term outcomes.5,6 On the other hand, percutaneous coronary intervention (PCI) has been widely carried out in clinical practice and has become one of the important means of treating AMI at the present stage. PCI can quickly open the narrowed or blocked blood vessels, improve the blood supply of ischemic myocardium and control the disease, thus greatly enhancing patient survival.7 However, clinical practice has found that some AMI patients still developed post-PCI HF, which can further cause cardiogenic shock, increase the risk of death, and seriously affect patient prognosis.8 Given this clinical dilemma, there remains an unmet need for reliable, early indicators that can identify patients at risk of developing post-PCI HF and delineate how ventricular remodeling differs dynamically between patients treated with PCI and those managed conservatively. Color Doppler echocardiography (cardiac color Doppler ultrasound) is the only non-invasive test that can dynamically display the internal structure of the cardiac cavity, cardiac pulsation, and blood flow.9 Recent studies have demonstrated that echocardiographic parameters-including left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV)-are independent predictors of long-term mortality and HF hospitalization in AMI patients following PCI,10 and advanced techniques such as two-dimensional speckle tracking echocardiography (2D-STE) have shown excellent performance in predicting LVR after PCI, with area under the curve (AUC) values reaching 0.85.11 However, the majority of these investigations have focused exclusively on PCI-treated cohorts without a conservatively managed control group, and among the limited studies that have included a conservative treatment arm for comparison, only a single post-treatment time point was assessed, without serial measurements to quantify the dynamic trajectory of ventricular remodeling from the immediate post-treatment period through mid-term follow-up.12–14 Therefore, this study investigated the performance of Color Doppler echocardiography in the dynamic assessment of ventricular remodeling in patients with AMI undergoing PCI and conservative treatment, and the predictive performance of HF after PCI. The overall goal is to provide a practical reference for the early risk stratification of this population. Materials and Methods This was a single-center, retrospective observational study conducted at The Affiliated Dongyang Hospital of Wenzhou Medical University. We retrospectively reviewed the medical records of patients with AMI admitted between March 2022 to January 2024. Data was extracted from the hospital’s electronic medical record system and the echocardiography image archiving database. The research protocol was approved by the Ethics Committee of The Affiliated Dongyang Hospital of Wenzhou Medical University (Ethics Approval Number: 2024-YX-224). The research subjects were 81 AMI patients, including 49 patients who underwent percutaneous coronary intervention plus guideline‑directed medical therapy (research group, RG) and 32 patients who received guideline‑directed medical therapy alone based on clinical circumstances (control group, CG). The study was conducted in strict accordance with the Declaration of Helsinki and all subjects signed informed consent. Criteria for Patient Enrollment and Exclusion Patients meeting the Fourth Universal Definition of Myocardial Infarction criteria for AMI were included:15,16 (1) elevated cardiac troponin I with at least one value above the 99th percentile upper reference limit; (2) typical ischemic chest pain lasting for > 30 min; and (3) typical electrocardiogram (ECG) dynamic changes, including new ST-segment elevation in at least two contiguous leads, new ST-segment depression, or new left bundle branch block. Exclusion criteria:17 (1) patients with dilated or hypertrophic cardiomyopathy, non-transmural (subendocardial) myocardial infarction, chronic renal insufficiency, other macrovascular diseases (such as severe valvular heart disease, aortic dissection) and recurrent myocardial infarction; (2) Patients who could not obtain complete echocardiographic follow-up data; (3) Patients who died within 6 months after the first AMI attack. Treatment Methods All patients in RG received PCI therapy and long-term postoperative administration of aspirin (100 mg/time, once/d) and clopidogrel (75 mg/time, once/d) or ticagrelor (180mg/time, second/d). Those without allergic history and related contraindications were additionally given angiotensin-converting enzyme inhibitors (ACEIs; captopril), beta-blockers (metoprolol) and statins (atorvastatin). CG patients did not receive PCI treatment due to delayed treatment outside the first PCI time window, refusal of invasive treatment by patients or their families, and PCI contraindications. All patients in the control group were treated with the following drugs, including aspirin, clopidogrel or ticagrelor, statins, beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor antagonists (ARBs). Color Doppler Echocardiography and Evaluation of HF HF occurring within 6 months after PCI was diagnosed according to the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: the presence of clinical symptoms and/or signs of heart failure (eg, dyspnea, orthopnea, lower extremity edema, or jugular venous distention) accompanied by objective evidence of cardiac dysfunction on echocardiography.18 The diagnosis was independently adjudicated by two cardiologists who reviewed the electronic medical records; any discrepancy was resolved by consensus. Left ventricular (LV) end‑diastolic dimension (LVEDD), LV end‑systolic diameter (LVESD), and LV ejection fraction (LVEF) were measured at baseline (1 day after treatment, T1) using a Philips iE33 cardiac color ultrasonic scanner. To dynamically assess ventricular remodeling, LV end‑diastolic volume (LVEDV) was additionally measured at 7 days (T2), 1 month (T3), and 6 months (T4) after treatment. The LV end‑diastolic volume index (LVEDVI) was calculated as LVEDV indexed to body surface area (BSA), where BSA was computed using the Mosteller formula: BSA (m2) = √([height (cm) × weight (kg)] / 3600).19 The LV end diastolic volume index (LVEDVI) was then calculated as LVEDV divided by body surface area. Ventricular remodeling was assessed by the serial change in LVEDVI. The difference between LVEDVI at each follow‑up time point (T2, T3, and T4) and the baseline value at T1 was defined as ΔLVEDVI. ΔLVEDVI ≥ 5 mL/m2 considered as ventricular remodeling.20 To minimize measurement bias, all echocardiographic images were acquired and analyzed independently by two experienced sonographers who were blinded to the patients’ treatment allocation and clinical outcomes. Statistical Analysis SPSS23.0 software was used for statistical analysis, and the significance threshold of P<0.05 was applicable to all analyses. Using the Shapiro–Wilk test before parametric comparisons. Between‑group differences in categorical variables [n (%)] were evaluated with the Chi‑square test, and differences in continuous variables () were assessed using the independent‑samples t‑test. For repeated measurements of ΔLVEDVI at T1-T4, one‑way analysis of variance (ANOVA) was performed; when the overall model was significant, Fisher’s least significant difference (LSD) post‑hoc test was applied to identify the time points at which the means diverged. The ability of baseline echocardiographic indices to discriminate between patients who did and did not develop post‑PCI heart failure was examined with receiver operating characteristic (ROC) analysis. In this model, the null hypothesis for each predictor was that its regression coefficient equals zero after adjustment for all other covariates.21 Results Comparison of Clinical Data The comparison of clinical baseline data between the two groups is shown in Table 1. There were no statistically significant differences in age, gender composition, smoking history, alcohol consumption, prevalence of diabetes mellitus, prevalence of hypertension, number of coronary artery lesions, baseline Gensini score, or place of residence between the CG and the RG (all P>0.05), which confirms that the two groups are comparable. Table 1Comparison of Clinical DataIndicatorsControl Group (n=32)Research Group (n=49)χ2 or tPAge63.50±13.7563.69±12.550.0650.948Gender0.0700.791Male24(75.00)38(77.55)Female8(25.00)11(22.45)Smoking0.3400.560Yes11(34.38)20(40.82)No21(65.63)29(59.18)Drinking alcohol0.1260.723Yes11(34.38)15(30.61)No21(65.63)34(69.39)Combined with diabetes mellitus0.0890.765Yes12(37.50)20(40.82)No20(62.50)29(59.18)Combined with hypertension0.0790.778Yes18(56.25)26(53.06)No14(43.75)23(46.94)Number of coronary lesions2.25±0.622.16±0.470.7120.479Baseline Gensini score30.66±7.3131.90±5.650.8600.392Place of residence0.3350.563Rural23(71.88)38(77.55)Urban9(28.13)11(22.45) Comparison of Clinical Data Comparison of Color Doppler Echocardiography results As shown in Figures 1 and 2, the occurrence of ventricular remodeling was observed in both groups within 6 months after treatment. The ΔLVEDVI values at T2-T4 in both groups were obviously higher than those at T1, peaking at T4 (P<0.05). Notably, at each time point from T2 to T4, the ΔLVEDVI was significantly lower in the RG than in the CG (P<0.05), suggesting that PCI treatment was associated with significant attenuation of progressive ventricular remodeling. Graphic shows cardiac function using a cardiac color ultrasonic scanner (Philips IE33). The cardiac function graphic of CG patients at the time of admission (A) and 6 months after treatment (B). The cardiac function graphic of RG patients at the time of admission (C) and 6 months after treatment (D). CG, control group; RG, research group. Dynamic changes in ΔLVEDVI from T1 to T4 in the PCI and conservative management groups. LVEDVI, left ventricular end‑diastolic volume index; vs. control group, *P<0.05; vs. T1, #P<0.05; vs. T2, &P<0.05; vs. T3, @P<0.05. Relationship Between Color Doppler Echocardiography results and PCI Treatment Effect Of the 49 patients in the RG, 11 developed HF within 6 months post-PCI and were classified as the risk group, while the remaining 38 patients who did not develop HF were classified as the safety group. Comparison of their color Doppler echocardiography at T1 (Figure 3) demonstrated that the HF group had significantly higher LVEDD and LVESD, and significantly lower LVEF, compared with the safety group (all P<0.05). Comparison of baseline (T1) echocardiographic parameters between patients who developed post‑PCI HF and those who did not. (A) LVEDD. (B) LVESD. (C) LVEF. HF, heart failure; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end‑systolic dimension; LVEF, left ventricular ejection fraction; *P<0.05. Evaluation of Color Doppler Echocardiography Results and Post-PCI HF The predictive performance of color Doppler echocardiographic parameters at T1 for HF within 6 months after PCI was assessed by ROC analysis, as shown in Figure 4 and Table 2. All three parameters demonstrated significant predictive value (all P<0.05). Specifically, LVEDD yielded an AUC of 0.768 (95% CI: 0.588–0.886) with a sensitivity of 90.91% and a specificity of 47.37% at a cutoff of >50.50 mm. LVESD showed improved performance, with an AUC of 0.801 (95% CI: 0.630–0.973), a sensitivity of 81.82%, and a specificity of 65.79% at a cutoff of >39.50 mm. Among the three parameters, LVEF demonstrated the strongest predictive performance, with an AUC of 0.885 (95% CI: 0.779–0.991), a sensitivity of 72.73%, and a specificity of 89.47% at a cutoff of <48.71% (P<0.001). ROC curves of baseline echocardiographic parameters for predicting post‑PCI heart failure. (A) LVEDD. (B) LVESD. (C) LVEF. ROC, receiver operating characteristic; PCI, percutaneous coronary intervention. Table 2ROC Analysis of Echocardiographic Parameters at T1 for Predicting Post‑PCI Heart FailureIndicatorsAUCStd. Error95% CIPCut-offSensitivity (%)Specificity (%)LVEDD (mm)0.7680.0760.588–0.8860.018>50.5090.9147.37LVESD (mm)0.8010.0880.630–0.9730.003>39.5081.8265.79LVEF (%)0.8850.0540.779–0.991<0.001<48.7172.7389.47Abbreviations: LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end‑systolic dimension; LVEF, left ventricular ejection fraction. ROC Analysis of Echocardiographic Parameters at T1 for Predicting Post‑PCI Heart Failure Abbreviations: LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end‑systolic dimension; LVEF, left ventricular ejection fraction. Comparison of Baseline Characteristics Between Patients with and without Post-PCI HF and Identification of Candidate Predictors To identify candidate variables for subsequent multivariable analysis, baseline clinical characteristics were compared between patients with and without post-PCI HF within the RG. As shown in Table 3, age, prevalence of hypertension and diabetes mellitus, number of coronary artery lesions, and Gensini score differed significantly between the two groups (all P<0.05), and were therefore entered into the multivariable logistic regression model as candidate predictors. Table 3Baseline Characteristics of Patients with versus without Post‑PCI HFIndicatorsSafety Group (n=38)Risk Group (n=11)χ2 or tPAge60.39±11.0275.09±11.083.891<0.001Gender1.5770.209Male31(81.58)7(63.64)Female7(18.42)4(36.36)Smoking0.1160.733Yes16(42.11)4(36.36)No22(57.89)7(63.64)Drinking alcohol0.0740.785Yes12(31.58)3(27.27)No26(68.42)8(72.73)Combined with diabetes mellitus5.9790.015Yes12(31.58)8(72.73)No26(68.42)3(27.27)Combined with hypertension8.1580.004Yes16(42.11)10(90.91)No22(57.89)1(9.09)Number of coronary lesions2.00±0.332.73±0.475.857<0.001Baseline Gensini score30.42±4.3737.00±6.743.866<0.001Place of residence0.1480.700Rural29(76.32)9(81.82)Urban9(23.68)2(18.18) Baseline Characteristics of Patients with versus without Post‑PCI HF Multivariate Analysis of HF After PCI Subsequently, variables with significant differences in clinical characteristics between the two groups were included in multivariate logistic analysis, and the results were shown in Table 4. In this exploratory multivariable model, hypertension (OR=3.887, 95% CI: 2.156–8.069), a greater number of coronary artery lesions (OR=2.842, 95% CI: 2.064–4.060), and a higher baseline Gensini score (OR=3.972, 95% CI: 2.752–5.933) were found to be significantly associated with the occurrence of HF after PCI (all P<0.05). Age and diabetes mellitus did not show a statistically significant independent association in this analysis (P>0.05). Given the limited number of HF events, these associations should be interpreted as exploratory and require validation in larger prospective studies. Table 4Multivariate Logistic Regression Analysis of HF After PCIIndicatorsΒS.E.Wald χ2POR95% CIAge0.1921.6222.1160.0870.9940.872–1.573Combined with diabetes mellitus0.6420.8421.8410.1241.2620.623–5.855Combined with hypertension−0.1921.66310.1460.0003.8872.156–8.069Number of coronary lesions−0.1681.04112.8750.0002.8422.064–4.060Baseline Gensini score0.7721.8739.7600.0003.9722.752–5.933 Multivariate Logistic Regression Analysis of HF After PCI Discussion With the development and continuous progress of clinical medical technology, cardiac color ultrasonic scanners are becoming increasingly advanced, with more powerful functions and mature technologies. For all kinds of complex cardiovascular diseases, this undoubtedly provides a good basis for diagnosis and treatment.22 Color Doppler echocardiography can intuitively and accurately judge the patients’ abnormal conditions such as cardiac function, myocardial lesions, ventricular wall thickness and atrioventricular diameter, which can provide valuable reference information for clinical diagnosis of AMI and ventricular remodeling.23 In the diagnosis and treatment of AMI, ventricular remodeling is one of the key issues worthies of attention. As we all know, ventricular remodeling is a progressive pathophysiological change of the heart that occurs during myocardial ischemia and other myocardial damage, and will eventually evolve into ventricular structure and function alterations.24 Cardiomyocyte apoptosis and necrosis caused by AMI is an important reason that affects ventricular remodeling, which is a compensatory change of the heart in order to maintain normal cardiac output and ventricular wall tension.25 Among the pathological mechanisms involved, a prolonged excessive inflammatory reaction to cardiomyocyte death and necrosis plays a crucial role.26 The results of this study found that patients with AMI could not avoid ventricular remodeling regardless of the treatment they were given. However, the development speed of ventricular remodeling decreased after PCI. We believe that this may be attributed to the loss of the myocardial contraction function caused by myocardial apoptosis and necrosis in the ischemic area after myocardial infarction, while the myocardium in the normal area can still contract and diastole normally, which leads to the uncoordinated ventricular contraction movement and the failure of the blood in the ventricle to be effectively discharged into the systemic circulation.27 As the blood remaining in the ventricle increases, the stress on the ventricular wall in diastolic and systolic phases as well as the pressure in the ventricular cavity increases, which can cause LV dilation in both the infarct and non-infarcted areas, resulting in morphological changes of the ventricular structure, including early infarcted area extension and later overall ventricular expansion, namely ventricular remodeling.28 Ventricular remodeling seriously damages patients’ LV function and increases complications, such as heart rupture and thrombosis, significantly elevating mortality. Therefore, delaying and trying to reverse LV remodeling has become the most important topic in the current cardiovascular field.29 Although the single echocardiographic parameters measured in this study-LVEF, LVEDD and LVESD-are recognized markers of cardiac function and remodeling, this study extends their application in two specific aspects. First, by comparing the continuous ΔLVEDVI measurements at four time points (T1-T4) between patients receiving PCI and those receiving conservative treatment, we provided direct quantitative evidence that PCI reduced progressive left ventricular dilatation characterized by poor remodeling. Although previous studies have shown that PCI can improve cardiac function, such as a large-scale study of 8181 patients showed that LVEF was significantly improved after PCI in patients with AMI, and the change of LVEF was independently associated with 5-year mortality.30 However, most studies only focused on cohorts treated with PCI, and there was no control group with conservative treatment.11 In limited studies including the comparison of conservative treatment groups, only one time point after treatment was evaluated, rather than continuous measurements to depict the dynamic trajectory of remodeling.31 Secondly, our results showed that the baseline echocardiographic parameters obtained as early as 1 day after treatment could effectively predict the occurrence of heart failure within 6 months after PCI intervention. The AUC of left ventricular ejection fraction was 0.885, the sensitivity was 72.73%, and the specificity was 89.47%. In previous studies, the early predictive performance of T1 has not been systematically evaluated for post-PCI HF identification, which may provide a practical window for enhanced monitoring and timely intervention, especially in environments with limited resources and inaccessible advanced imaging techniques. Meanwhile, recent advances in automated echocardiographic analysis-including cross-space consistency learning that embeds multi-level tasks into a unified latent space for multi-dimensional assessment and transformer-based segmentation networks with explicit superpixel constraints-have demonstrated promising improvements in measurement accuracy and inter-observer reproducibility.32,33 However, such advanced automated analysis tools were not incorporated in our study, which represents a potential area for methodological improvement in future investigations. Currently, PCI remains the mainstream method to treat AMI, but the postoperative situation of patients is still the focus of attention. In this study, patients who developed post-PCI HF had elevated LVEDD, and LVESD, lowered LVEF, and abnormal cardiac changes within 24 h after PCI compared with those without HF. Following the attack of AMI, ventricular remodeling can be triggered and the traction tension and pressure load carried by the ventricular wall can be reset and changed adaptively. In addition, the infarcted area can bulge or expand outwardly, while the ventricular wall in the non-infarct area is stretched and the tension load increases significantly, leading to abnormal ventricular wall pulsation, which in turn aggravates ventricular remodeling and trigger LV dysfunction, manifested as LVEDD, LVESD enlargement, and LVEF decrease on cardiac ultrasound images.34 Besides, the patient’s sympathetic nerve is excited and the cardiac cycle is shortened after the occurrence of AMI; moreover, the myocardial contraction is uncoordinated, the contraction force is weakened, the pressure of LV ejection into the aorta is weakened due to myocardial cell ischemia and necrosis, and the ejection time is shortened accordingly, which increases LVEDD and LVESD.35 This is also consistent with the results of previous studies, which can support our findings.36 Through ROC analysis, we demonstrated that color Doppler echocardiography parameters at T1 had significant predictive value for post-PCI HF, with LVEF exhibiting the strongest performance (AUC=0.885). Furthermore, in an exploratory multivariable logistic regression model, echocardiography results, along with number of coronary artery lesions, Gensini score, and hypertension were found to be significantly associated with the occurrence of HF after PCI (all P<0.05). These findings are consistent with previous work. For example, Song et al reported in their study that age, troponin levels, LVEF, and Gensini score are independent predictors of in-hospital HF in AMI patients after emergency PCI.37 In the study of Zhang et al, it was found that hypertension is an important contributor to major adverse cardiovascular events in ACS patients following PCI.38 However, given the limited number of HF events (n=11) in our study, the multivariable analysis should be regarded as exploratory, and the identified associations require validation in larger prospective cohorts. At present, color Doppler echocardiography parameters play a certain role in diagnosing and evaluating the condition of patients with heart diseases, and can reflect the cardiac function of patients more accurately and comprehensively.10 Our research provides additional evidence supporting the evaluation value of color Doppler echocardiography in AMI patients after PCI, which can help guide clinical workers to judge the prognosis of patients and formulate corresponding preventive measures to improve patient outcomes. However, several limitations of the present study should be acknowledged. First, the modest sample size, particularly the limited number of HF events (n=11), means that the multivariable logistic regression analysis should be regarded as exploratory, and the identified associations require validation in larger, prospective cohorts. Second, as a single-center retrospective study, the generalizability of our findings may be limited, and selection bias inherent to the non-randomized treatment allocation cannot be excluded. In addition, the short follow-up time may have been insufficient to capture late remodeling events and long-term clinical outcomes, for which extended observation is warranted. Furthermore, different ultrasonic instruments may also cause differences in examination results, and using more advanced instruments may obtain more accurate assessment of cardiac function. Future prospective, multicenter studies with larger sample sizes and longer follow-up periods are warranted to validate these findings and to determine whether early echocardiographic risk stratification can translate into improved clinical outcomes in this patient population. Conclusion Overall, this study showed that the increase in ΔLVEDVI was significantly attenuated in AMI patients undergoing PCI during the 6-month follow-up period compared with those receiving conservative treatment, indicating that PCI intervention may be associated with less obvious ventricular remodeling. In addition, echocardiographic parameters measured as early as one day after PCI, especially LVEF scores, have a good predictive value for identifying patients with post-PCI HF within six months. These findings suggest that color Doppler echocardiography may have the potential to serve as a clinical tool for dynamic assessment of early risk stratification of ventricular remodeling and heart failure after PCI intervention, providing valuable information for clinical decision-making. In conclusion, this study is a new supplement to the prognostic evaluation of post-PCI HF patients. Funding Statement There is no funding to report. Data Sharing Statement All the results are presented in the article. Further inquiries can be directed at the corresponding authors. Ethics Statement The research protocol was approved by the Ethics Committee of The Affiliated Dongyang Hospital of Wenzhou Medical University (Ethics Approval Number: 2024-YX-224). All experiments and procedures were performed according to the Declaration of Helsinki (as revised in 2013). Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References Associated Data Data Availability Statement All the results are presented in the article. Further inquiries can be directed at the corresponding authors.